Mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Affimer proteins were developed initially at the MRC Cancer Cell Unit in Cambridge then across two laboratories at the University of Leeds. Derived from the cysteine protease inhibitor family of cystatins, which function in nature as cysteine protease inhibitors, these 12–14 kDa proteins share the common tertiary structure of an alpha-helix lying on top of an anti-parallel beta-sheet. Affimer proteins display two peptide loops that can all be randomized to bind to desired target proteins, in a similar manner to monoclonal antibodies. Stabilization of the two peptides by the protein scaffold constrains the possible conformations that the peptides can take. This increases the binding affinity and specificity compared to libraries of free peptides, though can limit the target repertoire of Affimers.
Business biomimetics is the latest development in the application of biomimetics. Specifically it applies principles and practice from biological systems to business strategy, process, organization design, and strategic thinking. It has been successfully used by a range of industries in FMCG, defense, central government, packaging, and business services. Based on the work by Phil Richardson at the University of Bath the approach was launched at the House of Lords in May 2009. Generally, biometrics is used as a creativity technique that studies biological prototypes to get ideas for engineering solutions. In chemistry, a biomimetic synthesis is a chemical synthesis inspired by biochemical processes. Another, more recent meaning of the term bionics refers to merging organism and machine. This approach results in a hybrid system combining biological and engineering parts, which can also be referred as a cybernetic organism (cyborg). Practical realization of this was demonstrated in Kevin Warwick's implant experiments bringing about ultrasound input via his own nervous system.
The nobelium can then be isolated by exploiting its tendency to form the divalent state, unlike the other trivalent actinides: under typically used elution conditions (bis-(2-ethylhexyl) phosphoric acid (HDEHP) as stationary organic phase and 0.05 M hydrochloric acid as mobile aqueous phase, or using 3 M hydrochloric acid as an eluant from cation-exchange resin columns), nobelium will pass through the column and elute while the other trivalent actinides remain on the column. However, if a direct "catcher" gold foil is used, the process is complicated by the need to separate out the gold using anion-exchange chromatography before isolating the nobelium by elution from chromatographic extraction columns using HDEHP.
The study used a combination of existing, cheap drugs ahead of usual radiotherapy treatment. 24 October California-based startup Atom Computing announces a 1,225-qubit quantum computer, the first to break the 1,000+ barrier, which it plans to release in 2024. NASA provides updated details of its Nancy Grace Roman Space Telescope, planned for launch by 2027. JT-60SA, the world's largest fusion reactor, located in Japan, achieves first plasma. A study reviewing the 'planetary vital signs' reports deeply concerning patterns and records, minimal progress of mitigation by humanity, and a set of broad policy recommendations. It represents an annual update to a 2019 study that has been signed by now 15,000 researchers to track the state of climate change and its mitigation. 25 October – Scientists, helped by information derived from the Mars InSight lander, report that the planet Mars has a radioactive magma ocean under its crust. 26 October – Astronomers report studies that suggest for the first time that the planet Venus may have had plate tectonics during ancient times, and, as a result, may have had a cooler more habitable environment, and possibly one capable of generating life forms. 28 October – Positive results are reported in a study with rats of the experimental vaccine calixcoca meant for treating cocaine addiction. Clinical trials in humans are the next step of the study.
During the 13th century, Ghanaians developed their art of adinkra printing. Hand-printed and hand-embroidered adinkra clothes were made and used exclusively by royalty for devotional ceremonies. Each of the motifs that make up the corpus of adinkra symbolism has a name and meaning derived from a proverb, a historical event, human attitude, ethology, plant life-form, or shapes of inanimate and man-made objects. The meanings of the motifs may be categorised into aesthetics, ethics, human relations, and concepts. The Adinkra symbols have a decorative function as tattoos and also represent objects that encapsulate evocative messages that convey traditional wisdom, aspects of life, or the environment. There are symbols with meanings, with some linked with proverbs. In the words of Anthony Appiah, they were one of the means in a pre-literate society for "supporting the transmission of a complex and nuanced body of practice and belief". Kente cloth, the traditional or national cloth of Ghana, is worn by most southern Ghanaian ethnic groups, especially, the Akan Along with the adinkra cloth, Ghanaians use cloth fabrics for their traditional attire. The different ethnic groups have their own individual cloth. The most well known is the Kente cloth. Kente is a national costume and clothing, and these clothes are used to make traditional and modern Kente attire. Different symbols and colours mean different things. Kente is a ceremonial cloth hand-woven on a horizontal treadle loom and strips measuring about 4 inches wide are sewn together into larger pieces of cloths.
Sources: en.wikipedia.org
=== Spread === E. floccosum can remain viable for long periods of time by producing arthroconidia in skin scales. Arthroconidia are thick-walled spores with higher resistance to drying and heat conditions than mycelium. Arthroconidia formation allows E. floccosum to survive for years in showers, baths, swimming pools, towels, blankets, sheets, shoes and other clothing. The fungus commonly spreads by contact in showers and gym facilities.
RCH(NHP)CO2H + R'CH(NH2)CO2CH3 → RCH(NHP)C(O)NH(CHR')CO2CH3 + H2O Subsequent to this coupling reaction, the amine protecting group P and the ester are converted to the free amine and carboxylic acid, respectively. For many amino acids, the ancillary functional groups are protected. The condensation of the amine and the carboxylic acid to form the peptide bond generally employs coupling agents to activate the carboxylic acid. The Bergmann azlactone peptide synthesis is a classic organic synthesis for the preparation of dipeptides.
SR-17018 was subsequently assessed in rhesus monkeys and produced analgesic effects in this species that could be reversed by the MOR antagonist naltrexone, whereas respiratory depression could not be assessed due to solubility limitations. While conventional opioids like morphine produced robust itch-scratching behaviors, SR-17018 and buprenorphine only caused mild such effects, suggesting low-efficacy MOR activation. Although SR-17018 was reported to produce very little respiratory depression in mice, a subsequent study using oral administration instead of intraperitoneal administration, with the former having greater bioavailability, unexpectedly found significant respiratory depression with the drug. SR-17018 produced less analgesic tolerance than other MOR agonists in mice. Whereas morphine and oxycodone produced robust tolerance in the hot plate test with chronic administration, SR-17018 produced no or only slight tolerance in this assay depending on the dosage. In addition, whereas morphine caused MOR desensitization in the periaqueductal gray (PAG), a key brain area implicated in the analgesic effects of MOR agonists, SR-17018 produced no desensitization. Similarly, unlike morphine, SR-17018 did not cause upregulation of forskolin-stimulated cAMP accumulation in striatal membranes. Despite the preceding findings however, discontinuation of both morphine and SR-17018 caused withdrawal symptoms in mice, though withdrawal symptoms were lower with SR-17018 compared to morphine.
== Medical uses == Velmanase alfa is indicated for the treatment of the non-central nervous system manifestations of alpha-mannosidosis. Alpha-mannosidosis is a rare genetic lysosomal storage disorder. The symptoms of the disorder vary, but often include mild to moderate intellectual disability, hearing loss, weakened immune system, distinctive facial features (e.g., a large head, prominent forehead, and protruding jaw), skeletal abnormalities, and muscle weakness. Alpha-mannosidosis is caused by genetic changes in the MAN2B1 gene, which codes for the lysosomal alpha-mannosidase enzyme. Mutations of the MAN2B1 gene result in the lack of production of the alpha-D-mannosidase enzyme or the production of a defective, inactive form of the enzyme. Alpha-mannosidosis affects about 1 in every 500,000 people worldwide.
NaCl + H2SO4 → NaHSO4 + HCl When combined with nitric acid, sulfuric acid acts both as an acid and a dehydrating agent, forming the nitronium ion NO+2, which is important in nitration reactions involving electrophilic aromatic substitution. This type of reaction, where protonation occurs on an oxygen atom, is important in many organic chemistry reactions, such as Fischer esterification and dehydration of alcohols.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.